Abstract: AIM: To investigate the clinical efficacy of trimebutine maleate combined with Morita therapy in the treatment of patients with irritable bowel syndrome (IBS).METHODS: 108 patients were randomly assigned to two groups.Trimebutine maleate group (n= 54) was given trimebutine maleate 200 mg, po, tid, combined with Mortia therapy.The patients were analyzed by self-rating anxiety scale (SAS) and self-rating depression scale (SDS) before and after the treatment.Control group (n=54) was only given trimebutine maleate 200 mg, po, tid.The course was 4 weeks.RESULTS: The total efficacy rates were 87.04% and 72.22% in trimebutine maleate group and in control group, respectively. The therapeutic effects in trimebutine maleate group were better than those in the control group (P<0.05).The scores of SAS and SDS in trimebutine maleate group decreased significantly after the treatment (P<0.01). There were significant difference in recurrence rates between in trimebutine maleate group and in control group (P<0.01).CONCLUSION: The combination of trimebutine maleate combined with Morita therapy is an effective approach in treating IBS.

Key words: trimebutine maleate, Morita therapy, irritable bowel syndrome(IBS), self-rating anxiety scale(SAS), self-rating depression scale(SDS), bio-psychosocial medical model